Do Xanthine Oxidase Inhibitors reduce both Left Ventricular Hypertrophy and Vascular Dysfunction in Cardiovascular patients with Renal Dysfunction? - Allopurinol in LVH/CKD trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-004760-49-GB

Enrollment

Registered

2007-12-10

Start date

2008-01-02

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Stage 3 Left Ventricular Hypertrophy MedDRA version: 9.1 Level: LLT Classification code 10025164 Term: LVH MedDRA version: 9.1 Level: LLT Classification code 10064848 Term: Chronic kidney disease

Interventions

Trade Name: Allopurinol Product Name: Allopurinol Pharmaceutical Form: Capsule* INN or Proposed INN: ALLOPURINOL CAS Number: 315300 Pharmaceutical form of the placebo: Capsule* Route of administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Chronic Kidney Disease Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2) Patients with evidence of Echo Left Ventricular Hypertrophy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Known cardiac failure Patients with gout Patients with severe hepatic failure Patients already on Allopurinol Usual contraindications to MRI including metal implants in the body and claustrophobia Current immunosuppressive therapy (eg Azathioprine, Ciclosporin, Cyclophosphamide), warfarin, Chlorpropamide, Theophylline and 6 mercaptopurine Malignancy or other life threatening disease Pregnancy or lactating women Patients who unable to give informed consent (eg learning disabilities)

Design outcomes

Primary

Measure	Time frame
Main Objective: Does Allopurinol reduce left ventricular hypertrophy in cardiovascular patients with renal dysfunction?;Secondary Objective: Does Allopurinol reduce endothelial dysfunction in cardiovascular patients with renal dysfunction? ;Primary end point(s): Left Ventricular Hypertrophy regression on Cardiac MRI To see if Allopurinol improves peripheral endothelial function as assessed by Flow Mediated Dilatation (FMD)	—

Measure

Time frame

Main Objective: Does Allopurinol reduce left ventricular hypertrophy in cardiovascular patients with renal dysfunction?;Secondary Objective: Does Allopurinol reduce endothelial dysfunction in cardiovascular patients with renal dysfunction? ;Primary end point(s): Left Ventricular Hypertrophy regression on Cardiac MRI To see if Allopurinol improves peripheral endothelial function as assessed by Flow Mediated Dilatation (FMD)

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026